Det sekundære endepunkt, progressionsfri overlevelse, (PFS) viste 29% nedsat risiko for forværring eller død og en 22 måneder forbedring i median PFS (35, 5 måned for TPF og 13, 1 måned for PF).
The secondary endpoint, PFS, demonstrated a 29% risk reduction of progression or death and a 22 month improvement in median PFS (35.5 months for TPF and 13.1 for PF).